### Sofosbuvir

**Section:** 6. Anti-infective medicines > 6.4. Antiviral medicines > 6.4.4. Antiviral medicines for hepatitis C > Medicines for hepatitis C > Pangenotypic direct-acting antiviral combinations

**Indication**
- Chronic hepatitis C

**INN**
- Sofosbuvir

**Medicine type**
- Chemical agent

**List type**
- Core

**Additional notes**
- Pangenotypic when used in combination with daclatasvir or ravidasvir.

**Formulations**
- Oral > Solid: 400 mg ; 200 mg

**EML status history**
- First added in 2015 (TRS 994)
- Changed in 2019 (TRS 1021)
- Changed in 2021 (TRS 1035)
- Changed in 2023 (TRS 1049)

**Sex**
- All

**Age**
- Also recommended for children

**Therapeutic alternatives**
- Medicines within the same pharmacological class can be used

**Therapeutic alternatives limitations**
- Pangenotypic direct-acting antiviral combinations

**Patent information**
- Main patent is active in several jurisdictions. For more information on specific patents and license status for developing countries visit [www.MedsPal.org](http://www.MedsPal.org)

**Wikipedia**
- Sofosbuvir

**DrugBank**
- Sofosbuvir

---

**Summary of evidence and Expert Committee recommendations**

The note associated with the listing of sofosbuvir was updated following the recommendation to include ravidasvir on the EML.